ClinicalTrials.gg
CompletedNCT02264132Updated Oct 15, 2014

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

A Phase 1 interventional study of Pramipexole ER tablet and Pramipexole IR tablet in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

The objectives of this study were to investigate relative BA at steady state and to investigate dose proportionality of pharmacokinetic parameters

Relative BA at steady state:

  • Pramipexole 0.375 mg ER tablet q.d. versus pramipexole 0.125 mg IR tablet t.i.d.
  • Pramipexole 1.5 mg ER tablet q.d. versus pramipexole 0.5 mg IR tablet t.i.d.

Dose proportionality of pharmacokinetic parameters:

  • Pramipexole ER dosages from 0.375 to 1.5 mg q.d.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects participating in the study are healthy male volunteers
  • Age between 20 and 40 years
  • (BMI) between 17.6 and 26.4 kg/m2
  • All volunteers must give written before screening to participate in this study and before first drug administration on Day 1 at Visit 2

Exclusion criteria

Exclusion Criteria:

  • Any findings of the medical examination (including blood pressure, pulse rate, , and laboratory test parameters) of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy), psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than ten half-lives of the respective drug before the administration of products
  • Use of any drugs which might influence the results of the trial within 7 days before the start of drug administration in the study or during the study period
  • Participation in another trial with an investigational drug (within 4 months before the start of drug administration)
  • Smoker (>10 cigarettes or >3 cigars or >3 pipes/day and who cannot refrain from smoking at the trial site)
  • Alcohol abuse (>40 g/day)
  • Drug abuse
  • Blood donation (≥100 mL within 4 weeks before drug administration or during the trial)
  • Excessive physical activities from 7 days before the start of drug administration to the end of this study
  • Any positive results in surface antigen (HBsAg), anti hepatitis B core (HBc) antibodies, anti virus (HCV) antibodies and (HIV) test

The following exclusion criteria are of special interest for this study:

  • Hypersensitivity to pramipexole or other dopamine agonists
  • Supine blood pressure at screening of systolic \<110 mmHg and diastolic \<60 mmHg
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Pramipexole ER tablet versus Pramipexole IR tablet

    Drug: Pramipexole ER tablet · Drug: Pramipexole IR tablet

  • Experimental
    Pramipexole IR tablet versus Pramipexole ER tablet

    Drug: Pramipexole ER tablet · Drug: Pramipexole IR tablet

06

What researchers measure

Primary outcomes

  1. AUCτ,ss=AUC0-24,ss for ER (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=24 hours)

    Time frame: up to day 5

  2. AUC0-24,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours at steady state) (This parameter was calculated as 3 times of AUC0-8,ss.)

    Time frame: up to 24 hours after drug administration

Secondary outcomes

  1. Ae0-24,ss (amount of analyte that is eliminated in urine from 0 to 24 hours at steady state)

    Relative BA

    Time frame: up to 24 hours after drug administration

  2. AUCτ,ss=AUC0-24,ss for ER (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=24 hours)

    Dose proportionality (only for ER)

    Time frame: up to 24 hours after drug administration

  3. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)

    Dose proportionality (only for ER)

    Time frame: up to day 5

  4. Ae0-24,ss (amount of analyte that is eliminated in urine from 0 to 24 hours at steady state)

    Dose proportionality (only for ER)

    Time frame: up to 24 hours after drug administration

  5. AUCτ,ss=AUC0-24,ss for ER (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=24 hours)

    Time frame: up to 24 hours after drug administration

  6. AUC0-24,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours at steady state) (This parameter was calculated as 3 times of AUC0-8,ss.)

    Time frame: up to 24 hours after drug administration

  7. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)

    Time frame: up to day 5

  8. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state)

    Time frame: up to day 5

  9. PTF (peak-trough fluctuation)

    Time frame: up to day 5

  10. tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state)

    Time frame: up to day 5

  11. Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)

    Time frame: up to day 5

  12. Cavg (average concentration of the analyte in plasma at steady state)

    Time frame: up to day 5

  13. t1/2,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: up to day 5

  14. CL/F,ss (apparent clearance of the analyte in plasma at steady state after

    Time frame: up to day 5

  15. CLR,ss (renal clearance of the analyte at steady state determined over the dosing interval τ)

    Time frame: up to day 5

  16. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following oral administration)

    Time frame: up to day 5

  17. Ae0-24,ss (amount of analyte that is eliminated in urine from 0 to 24 hours at steady state)

    Time frame: up to 24 hours after drug administration

  18. Ae0-8,ss for IR (amount of analyte that is eliminated in urine from 0 to 8 hours at steady state)

    Time frame: up to 8 hours after drug administration

  19. AUC0-8,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 8 hours at steady state)

    Time frame: up to 8 hours after drug administration

  20. Number of subjects with adverse events

    Time frame: up to 7 days after last drug administration

  21. Assessment of tolerability by investigator on a 4-point scale

    Time frame: Day 5

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a primary completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2014
First posted
Oct 15, 2014
Start
Sep 2006
Primary completionActual
Nov 2006
Last update
Oct 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02264132
Responsible party
Sponsor
First posted
Oct 15, 2014
Start date
Sep 2006
Primary completion
Nov 2006
Last update
Oct 15, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion